These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

678 related items for PubMed ID: 24145347

  • 1. Progression in smoldering myeloma is independently determined by the chromosomal abnormalities del(17p), t(4;14), gain 1q, hyperdiploidy, and tumor load.
    Neben K, Jauch A, Hielscher T, Hillengass J, Lehners N, Seckinger A, Granzow M, Raab MS, Ho AD, Goldschmidt H, Hose D.
    J Clin Oncol; 2013 Dec 01; 31(34):4325-32. PubMed ID: 24145347
    [Abstract] [Full Text] [Related]

  • 2. Combining information regarding chromosomal aberrations t(4;14) and del(17p13) with the International Staging System classification allows stratification of myeloma patients undergoing autologous stem cell transplantation.
    Neben K, Jauch A, Bertsch U, Heiss C, Hielscher T, Seckinger A, Mors T, Müller NZ, Hillengass J, Raab MS, Ho AD, Hose D, Goldschmidt H.
    Haematologica; 2010 Jul 01; 95(7):1150-7. PubMed ID: 20220069
    [Abstract] [Full Text] [Related]

  • 3. Molecular cytogenetic aberrations in patients with multiple myeloma studied by interphase fluorescence in situ hybridization.
    Chen L, Li J, Xu W, Qiu H, Zhu Y, Zhang Y, Duan L, Qian S, Lu H.
    Exp Oncol; 2007 Jun 01; 29(2):116-20. PubMed ID: 17704743
    [Abstract] [Full Text] [Related]

  • 4. Chromosome 1 amplification has similar prognostic value to del(17p13) and t(4;14)(p16;q32) in multiple myeloma patients: analysis of real-life data from the Polish Myeloma Study Group.
    Grzasko N, Hajek R, Hus M, Chocholska S, Morawska M, Giannopoulos K, Czarnocki K, Druzd-Sitek A, Pienkowska-Grela B, Rygier J, Usnarska-Zubkiewicz L, Dytfeld D, Kubicki T, Jurczyszyn A, Korpysz M, Dmoszynska A.
    Leuk Lymphoma; 2017 Sep 01; 58(9):1-15. PubMed ID: 28092996
    [Abstract] [Full Text] [Related]

  • 5. Impact of genetic abnormalities on survival after allogeneic hematopoietic stem cell transplantation in multiple myeloma.
    Schilling G, Hansen T, Shimoni A, Zabelina T, Pérez-Simón JA, Gutierrez NC, Bethge W, Liebisch P, Schwerdtfeger R, Bornhäuser M, Otterstetter S, Penas EM, Dierlamm J, Ayuk F, Atanackovic D, Bacher U, Bokemeyer C, Zander A, San Miguel J, Nagler A, Kröger N.
    Leukemia; 2008 Jun 01; 22(6):1250-5. PubMed ID: 18418408
    [Abstract] [Full Text] [Related]

  • 6. Timing of acquisition of deletion 13 in plasma cell dyscrasias is dependent on genetic context.
    Chiecchio L, Dagrada GP, Ibrahim AH, Dachs Cabanas E, Protheroe RK, Stockley DM, Orchard KH, Cross NC, Harrison CJ, Ross FM, UK Myeloma Forum.
    Haematologica; 2009 Dec 01; 94(12):1708-13. PubMed ID: 19996118
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Predictive role of interphase cytogenetics for survival of patients with multiple myeloma.
    Königsberg R, Zojer N, Ackermann J, Krömer E, Kittler H, Fritz E, Kaufmann H, Nösslinger T, Riedl L, Gisslinger H, Jäger U, Simonitsch I, Heinz R, Ludwig H, Huber H, Drach J.
    J Clin Oncol; 2000 Feb 01; 18(4):804-12. PubMed ID: 10673522
    [Abstract] [Full Text] [Related]

  • 9. Gain of 1q21 is an unfavorable genetic prognostic factor for multiple myeloma patients treated with high-dose chemotherapy.
    Nemec P, Zemanova Z, Greslikova H, Michalova K, Filkova H, Tajtlova J, Kralova D, Kupska R, Smetana J, Krejci M, Pour L, Zahradova L, Sandecka V, Adam Z, Buchler T, Spicka I, Gregora E, Kuglik P, Hajek R.
    Biol Blood Marrow Transplant; 2010 Apr 01; 16(4):548-54. PubMed ID: 20005965
    [Abstract] [Full Text] [Related]

  • 10. Interphase fluorescence in situ hybridization in multiple myeloma and monoclonal gammopathy of undetermined significance without and with positive plasma cell identification: analysis of 192 cases from the Region of Southern Denmark.
    Christensen JH, Abildgaard N, Plesner T, Nibe A, Nielsen O, Sørensen AG, Kerndrup GB, Leukemia/Lymphoma Study Group, Region of Southern Denmark.
    Cancer Genet Cytogenet; 2007 Apr 15; 174(2):89-99. PubMed ID: 17452249
    [Abstract] [Full Text] [Related]

  • 11. Additional genetic abnormalities significantly worsen poor prognosis associated with 1q21 amplification in multiple myeloma patients.
    Grzasko N, Hus M, Pluta A, Jurczyszyn A, Walter-Croneck A, Morawska M, Chocholska S, Hajek R, Dmoszynska A.
    Hematol Oncol; 2013 Mar 15; 31(1):41-8. PubMed ID: 22674819
    [Abstract] [Full Text] [Related]

  • 12. [Comparative study of genetic aberrations in human multiple myeloma cell lines and newly diagnosed MM by fluorescence in situ hybridization].
    An G, Xie ZQ, Li CH, Li Q, Yi SH, Qiu LG.
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Dec 15; 18(6):1505-10. PubMed ID: 21176360
    [Abstract] [Full Text] [Related]

  • 13. Long-term analysis of the IFM 99 trials for myeloma: cytogenetic abnormalities [t(4;14), del(17p), 1q gains] play a major role in defining long-term survival.
    Avet-Loiseau H, Attal M, Campion L, Caillot D, Hulin C, Marit G, Stoppa AM, Voillat L, Wetterwald M, Pegourie B, Voog E, Tiab M, Banos A, Jaubert J, Bouscary D, Macro M, Kolb B, Traulle C, Mathiot C, Magrangeas F, Minvielle S, Facon T, Moreau P.
    J Clin Oncol; 2012 Jun 01; 30(16):1949-52. PubMed ID: 22547600
    [Abstract] [Full Text] [Related]

  • 14. Baseline characteristics, chromosomal alterations, and treatment affecting prognosis of deletion 17p in newly diagnosed myeloma.
    Merz M, Hielscher T, Seckinger A, Hose D, Mai EK, Raab MS, Goldschmidt H, Jauch A, Hillengass J.
    Am J Hematol; 2016 Nov 01; 91(11):E473-E477. PubMed ID: 27508939
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. [Correlation between chromosome 13q14 deletion and 1q abnormality in multiple myeloma].
    Chen LJ, Li JY, Zhu Y, Wang XW, Qiu HR, Yang RF, Xu W, Xu JR, Lu H.
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2009 Feb 01; 26(1):102-5. PubMed ID: 19199264
    [Abstract] [Full Text] [Related]

  • 17. 14q32 translocations and monosomy 13 observed in monoclonal gammopathy of undetermined significance delineate a multistep process for the oncogenesis of multiple myeloma. Intergroupe Francophone du Myélome.
    Avet-Loiseau H, Facon T, Daviet A, Godon C, Rapp MJ, Harousseau JL, Grosbois B, Bataille R.
    Cancer Res; 1999 Sep 15; 59(18):4546-50. PubMed ID: 10493504
    [Abstract] [Full Text] [Related]

  • 18. [Genetic abnormalities in multiple myeloma: role in oncogenesis and impact on survival].
    Decaux O, Lodé L, Minvielle S, Avet-Loiseau H.
    Rev Med Interne; 2007 Oct 15; 28(10):677-81. PubMed ID: 17559979
    [Abstract] [Full Text] [Related]

  • 19. The progression from MGUS to smoldering myeloma and eventually to multiple myeloma involves a clonal expansion of genetically abnormal plasma cells.
    López-Corral L, Gutiérrez NC, Vidriales MB, Mateos MV, Rasillo A, García-Sanz R, Paiva B, San Miguel JF.
    Clin Cancer Res; 2011 Apr 01; 17(7):1692-700. PubMed ID: 21325290
    [Abstract] [Full Text] [Related]

  • 20. [Correlation of chromosomal aberrations with prognostic markers in multiple myeloma patients--a single institution study].
    Lee JW, Lee JK, Hong YJ, Hong SI, Chang YH.
    Korean J Lab Med; 2008 Dec 01; 28(6):413-8. PubMed ID: 19127104
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 34.